Micro-cap biotech developing Buntanetap for Alzheimer's and Parkinson's disease. No dividend, beta ~1.6, market cap under $65M. Thin liquidity, wide spreads — options rarely viable for meaningful CSP strategies.
These free tools show market conditions and individual scores.
Our daily research goes deeper — covering option-specific data points, strike analysis, and risk metrics delivered via Telegram.